Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES StudyCristina Masini, Carmine Pinto, Sebastiano Buti et al.|European Urology|2021Cited by 110
NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).Cristina Masini, Carmine Pinto, Cinzia Iotti et al.|Journal of Clinical Oncology|2018Cited by 5